<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04928534</url>
  </required_header>
  <id_info>
    <org_study_id>IRB2021-YX-056-01</org_study_id>
    <nct_id>NCT04928534</nct_id>
  </id_info>
  <brief_title>Cohort Study of Blood Biomarkers for TES</brief_title>
  <official_title>Observational Cohort Study of Blood Transcriptomics and Proteomics Information as Biomarkers of Traumatic Encephalopathy Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tianjin Medical University General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tianjin Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, high-throughput screening and multi-omics (transcriptomics and proteomics)&#xD;
      joint analysis technology will be employed to explore potential CTE/TES biomarkers (RNA and&#xD;
      protein) in blood and its exosomes. Thereafter, these biomarkers will be combined with the&#xD;
      reported TBI biomarkers to create a novel set of CTE/TES molecular diagnostic signatures. The&#xD;
      findings may open a new avenue for the clinical diagnosis of the disease and the future&#xD;
      research on its therapeutic strategy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Blood level of novel protein biomarkers for CTE/TES</measure>
    <time_frame>Baseline</time_frame>
    <description>Novel protein biomarkers for CTE/TES will be screened out by transcriptomics + proteomics high-throughput detection and multi-omics bioinformatics analysis. Their levels will be further verified using ELISA assay.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood level of novel RNA biomarkers for CTE/TES</measure>
    <time_frame>Baseline</time_frame>
    <description>Novel RNA biomarkers for CTE/TES will be screened out by transcriptomics + proteomics high-throughput detection and multi-omics bioinformatics analysis. Their levels will be further verified using RT-PCR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood level of classical biomarkers for CTE/TES</measure>
    <time_frame>Baseline</time_frame>
    <description>Blood S100B, GFAP, UCH-L1, NFL, T-Tau and p-Tau181 level detected by ELISA assay</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Chronic Traumatic Encephalopathy</condition>
  <condition>Traumatic Encephalopathy, Chronic</condition>
  <condition>Traumatic; Encephalopathy, Postcontusional</condition>
  <arm_group>
    <arm_group_label>Athletes with rmTBI history</arm_group_label>
    <description>50 active or retired athletes from the Weightlifting, Wrestling, Judo, Boxing and Taekwondo Sports Management Center of Tianjin Sports Bureau</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with rmTBI history</arm_group_label>
    <description>50 patients with multiple (≥2 times) exposure to brain trauma attending Tianjin Medical Insurance designated hospitals such as Tianjin Medical University General Hospital</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteer</arm_group_label>
    <description>20 healthy volunteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood tests, Cognitive function tests, head MRI (plain scan and DTI sequence) examination and head PET (FDG-PET, Tau-PET and Amyloid-PET) examination</intervention_name>
    <description>Blood tests (30-ml venous blood) for the following items. 1) Transcriptomics and proteomics high-throughput detection and quantitative verification; 2) Exosomal transcriptomics and proteomics high-throughput detection and quantitative verification; 3) Quantitative detection for classical biomarkers of traumatic brain injury, including S100B, GFAP, UCH-L1, NFL, T-Tau and p-Tau181.&#xD;
Cognitive function tests, including RPQ, MMSE and MoCA.&#xD;
Possible head MRI (plain scan and DTI sequence) examination and head PET (FDG-PET, Tau-PET and Amyloid-PET) examination</description>
    <arm_group_label>Athletes with rmTBI history</arm_group_label>
    <arm_group_label>Healthy volunteer</arm_group_label>
    <arm_group_label>Patients with rmTBI history</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        -  Athletes with rmTBI history. The subjects are active or retired athletes who have&#xD;
             engaged in weightlifting, wrestling, judo, boxing or taekwondo. All of them have a&#xD;
             clear history of rmTBI.&#xD;
&#xD;
          -  Patients with rmTBI history. The subjects have a history of multiple (≥2 times)&#xD;
             exposure to brain trauma, and medical records in Tianjin Medical Insurance designated&#xD;
             hospitals.&#xD;
&#xD;
          -  Healthy volunteers, without rmTBI history.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Athletes and patients with traumatic brain injury&#xD;
&#xD;
               -  Age ≥ 18 and ≤ 80 years old with independent behavior ability or authorized legal&#xD;
                  representative.&#xD;
&#xD;
               -  Have a clear history of repetitive mild TBI, concussion or subconcussion.&#xD;
&#xD;
               -  The most recent head injury occurred 3 months ago.&#xD;
&#xD;
          2. Healthy Volunteers&#xD;
&#xD;
               -  Age ≥ 18 and ≤ 80 years old with independent behavior ability.&#xD;
&#xD;
               -  No history of repetitive mild TBI, concussion or subconcussion.&#xD;
&#xD;
               -  Fully understands the nature of the study, and voluntarily participates and signs&#xD;
                  the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Athletes and patients with traumatic brain injury&#xD;
&#xD;
               -  Pregnant or lactating women.&#xD;
&#xD;
               -  History of other neurological diseases.&#xD;
&#xD;
               -  History of tumors, hematological diseases, severe cardiopulmonary diseases,&#xD;
                  hepatic failure or renal failure.&#xD;
&#xD;
               -  Have participated in clinical trials in the past four weeks.&#xD;
&#xD;
               -  The investigator believes that not appropriate for inclusion.&#xD;
&#xD;
          2. Healthy Volunteers&#xD;
&#xD;
               -  Pregnant or lactating women.&#xD;
&#xD;
               -  History of TBI or other neurological diseases.&#xD;
&#xD;
               -  History of tumors, hematological diseases, severe cardiopulmonary diseases,&#xD;
                  hepatic failure or renal failure.&#xD;
&#xD;
               -  Have participated in clinical trials in the past four weeks.&#xD;
&#xD;
               -  The investigator believe that not appropriate for inclusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ping Lei, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tianjin Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xintong Ge, Doctor</last_name>
    <phone>86-022-60364359</phone>
    <email>xge@tmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fanglian Chen</last_name>
      <phone>86-022-60362237</phone>
      <email>chenfanglian1976@163.com</email>
    </contact>
    <investigator>
      <last_name>Xintong Ge, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 6, 2021</study_first_submitted>
  <study_first_submitted_qc>June 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2021</study_first_posted>
  <last_update_submitted>June 26, 2021</last_update_submitted>
  <last_update_submitted_qc>June 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tianjin Medical University General Hospital</investigator_affiliation>
    <investigator_full_name>Xintong Ge</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Chronic Traumatic Encephalopathy</mesh_term>
    <mesh_term>Brain Damage, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 10, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/34/NCT04928534/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 10, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/34/NCT04928534/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

